2ndB is creating a new preclinical in-vitro test (a brain-on-chip), capable of accurately predicting clinical efficacy, increasing the rate of success in drug development, reducing overall cost and accelerating the development of curative solutions for NDDs.

The focus in the 3D Lab is how we can use 3D technologies to improve care for each individual patient. These new technologies help improve the care and the treatment plan of patients, while taking their specific individual needs and wishes into consideration.

AGILeBiotics is committed to contribute to the fight against bacterial resistance by bringing new therapeutic solutions to patients infected by multidrug resistant bacteria.

AmbAgon develops first-in-class small-molecule therapeutics for breast cancer by augmenting the tumor-suppressing functions of the 14-3-3 protein.

Leveraging Human Cellular Models to Develop Effective Therapies for Cardiac Arrhythmias.

Ardim develops certified AI-based smartphone applications which enable medical imaging at the point-of-care. The point-of-care ultrasound market is growing fast into a multibillion market.

ARTIC offers a “Magnetic Artificial Cilia (MAC) pump”: a chip-sized, modular and tubeless flow system that eliminates manual handling, enables automation and higher throughput, does not interfere with circulating cells and provides physiological flow for a range of organ models.

It is the mission of ARTPred to make our unique technology available for all IVF patients worldwide in order to avoid unnecessary treatment burden.

Astherna is developing a treatment for Stargardt disease (STGD1) based on antisense oligonucleotides (AONs).

The Trammpolin® meniscus prosthesis is an anatomically shaped, non-biodegradable polymer meniscus implant designed to mimic the function of the natural meniscus and functions as a shock absorber by adequate load distribution within the knee joint.